Compare · CI vs KEQU
CI vs KEQU
Side-by-side comparison of The Cigna Group (CI) and Kewaunee Scientific Corporation (KEQU): market cap, price performance, sector, and recent activity on the wire.
Summary
- CI operates in Health Care, while KEQU operates in Industrials - the two are in different parts of the market.
- CI is the larger of the two at $78.04B, about 755.8x KEQU ($103.2M).
- Over the past year, CI is down 5.9% and KEQU is down 6.0% - CI leads by 0.1 points.
- CI has hit the wire 4 times in the past 4 weeks while KEQU has been quiet.
- CI has more recent analyst coverage (25 ratings vs 0 for KEQU).
- Company
- The Cigna Group
- Kewaunee Scientific Corporation
- Price
- $295.00+1.90%
- $36.95+5.05%
- Market cap
- $78.04B
- $103.2M
- 1M return
- +2.39%
- +5.05%
- 1Y return
- -5.95%
- -6.04%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 4
- 0
- Recent ratings
- 25
- 0
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Kewaunee Scientific Corporation
Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. It operates in two segments, Domestic and International. The company's products include steel, wood, laminate furniture, fume hoods, biological safety cabinets, laminar flow and ductless hoods, adaptable modular and column systems, moveable workstations and carts, epoxy resin worksurfaces, sinks, and accessories and related design services. Its laboratory products are used in chemistry, physics, biology, and other general science laboratories in the pharmaceutical, biotechnology, industrial, chemical, commercial, educational, government, and health care markets; technical products are used in facilities manufacturing computers and light electronics and by users of computer and networking furniture; and laminate caseworks that are used in educational, healthcare, and industrial applications. The company sells its products primarily through dealers, commissioned agents, and a national distributor, as well as through competitive bids submitted by the company and its subsidiaries in Singapore, India, and China. Kewaunee Scientific Corporation was founded in 1906 and is headquartered in Statesville, North Carolina.
Latest CI
- EVP, Global CIO Koka Durga Prasad covered exercise/tax liability with 729 shares, decreasing direct ownership by 10% to 6,552 units (SEC Form 4) (withholding tax)
- SEC Form 4 filed by Director Kurian George
- The Cigna Group downgraded by Barclays with a new price target
- The Cigna Group downgraded by Deutsche Bank with a new price target
- Chairman & CEO Cordani David exercised 212,543 shares at a strike of $170.34 and sold $59,114,186 worth of shares (201,878 units at $292.82) as part of a pre-agreed trading plan, increasing direct ownership by 23% to 57,766 units (SEC Form 4)
- The Cigna Group filed SEC Form 8-K: Regulation FD Disclosure
- The Cigna Group Announces Appearance at the BofA Securities 2026 Health Care Conference
- Kayne Anderson Energy Infrastructure Fund Announces Appointment of Michael J. Hennigan as New Independent Director
- SEC Form 144 filed by The Cigna Group
- SEC Form 10-Q filed by The Cigna Group
Latest KEQU
- Director Gehl Keith M was granted 2,013 shares, increasing direct ownership by 10% to 22,409 units (SEC Form 4)
- Director Campbell John Jette was granted 2,013 shares, increasing direct ownership by 292% to 2,703 units (SEC Form 4)
- Kewaunee Scientific Corporation Appoints Jorge Santos as Vice President of International Sales, Laboratory Products Group
- SEC Form 4 filed by Pyle Margaret B
- SEC Form 10-Q filed by Kewaunee Scientific Corporation
- Kewaunee Scientific Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Kewaunee Scientific Reports Results for Third Quarter of Fiscal Year 2026
- Kewaunee Scientific and Nu Aire Inc. to Attend analytica 2026 in Munich
- Kewaunee Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Kewaunee Scientific to Report Results for Third Quarter Fiscal Year 2026